New variant of varicella-zoster virus

Emerging Infectious Diseases

Volumn 8, Issue 12, 2002, Pages 1504-1505

  Tipples, Graham A ^a   Stephens, Gwen M ^b   Sherlock, Chris ^b   Bowler, Margrit ^b   Hoy, Benny ^c   Cook, Darrel ^c   Grose, Charles ^d  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

^c BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E; MONOCLONAL ANTIBODY;

ARTICLE; CHICKENPOX; HERPES ZOSTER; NONHUMAN; SEROTYPE; VARICELLA ZOSTER VIRUS; VIRUS ISOLATION; VIRUS MUTANT; VIRUS MUTATION;

EID: 0036913489     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0812.020118     Document Type: Article

References (15)

1. Santos RA, Padilla JA, Hatfield C, Grose C. Antigenic variation of varicella zoster virus Fc receptor gE: Loss of a major B cell epitope in the ectodomain. Virology 1998;249:21-31.
2. Santos RA, Hatfield CC, Cole NL, Padilla JA, Moffat JF, Arvin AM, et al. Varicella-zoster virus gE escape mutant VZV-MSP exhibits an accelerated cell-to-cell spread phenotype in both infected cell cultures and SCID-hu mice. Virology 2000;275:306-17.
3. Straus SE, Hay J, Smith H, Owens J. Genome differences among varicella-zoster virus isolates. J Gen Virol 1983;64:1031-41.
4. Gharabaghi F, Aymard M, Trotemann P, Gerdil C. A rapid and simplified micromethod for subtyping varicella-zoster virus. J Med Virol 1990;31:129-34.
5. Kinchington PR, Turse SE. Molecular basis for a geographic variation of varicella-zoster virus recognized by a peptide antibody. Neurology 1995;45(Suppl 8):S13-4.
6. Hawrami K, Breuer J. Analysis of United Kingdom wild-type strains of varicella-zoster virus: Differentiation from the Oka vaccine strain. J Med Virol 1997;53:60-2.
7. LaRussa P, Steinberg S, Arvin A, Dwyer D, Burgess M, Menegus M, et al. Polymerase chain reaction and restriction fragment length polymorphism analysis of varicella-zoster virus isolates from the United States and other parts of the world. J Infect Dis 1998;178 (Suppl 1):S64-6.
8. Loparev VN, Argaw T, Krause PR, Takayama M, Schmid DS. Improved identification and differentiation of varicella-zoster virus wild-type strains and an attenuated varicella vaccine strain using a VZV open reading frame 62-based PCR. J Clin Microbiol 2000;38:3156-60.
9. Rentier B. Introduction to the proceedings of the Second International Conference on the Varicella-zoster virus. Neurology 1995;45(Suppl 8):S8.
10. Davison AJ, Scott JE. The complete DNA sequence of Varicella-Zoster Virus. J Gen Virol 1986;67:1759-816.
11. Faga B, Maury W, Bruckner DA, Grose C. Identification and mapping of single nucleotide polymophisms in the varicella-zoster virus genome. Virology 2001;280:1-6.
12. Grose C, Edwards DP, Friedrichs WE, Weigle KA, McGuire WL. Monoclonal antibodies against three major glycoproteins of varicella-zoster virus. Infect Immun 1983;40:381-8.
13. Ito M, Ihara T, Grose C, Starr S. Human leukocytes kill varicella-zoster virus-infected fibroblasts in the presence of murine monocional antibodies to virus-specific glycoproteins. J Virol 1985;54:98-102.
14. Ciurea A, Klenerman P, Hunziker L, Horvath E, Senn BM, Ochsenbein AF, et al. Viral persistence in vivo through selection of neutralizing antibody-escape variants. Proc Natl Acad Sci U S A 2000;97:2749-54.
15. Shankar V, Fisher S, Forghani B, Vafai A. Nucleotide sequence analysis of varicella-zoster virus glycoprotein E epitope coding regions. Vaccine 2001;19:3830-3.